Pimozide is under clinical development by Modelis and currently in Phase II for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase II drugs for Amyotrophic Lateral Sclerosis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pimozide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pimozide is under development for the treatment of amyotrophic lateral sclerosis (ALS). It is administered through oral route and acts by targeting D2 dopamine receptor.
Modelis is a drug discovery company for rare and genetic diseases. Modelis is headquartered in Montreal, Quebec, Canada.
For a complete picture of Pimozide’s drug-specific PTSR and LoA scores, buy the report here.